MX369818B - Compuestos selectivos de peptido yy (pyy) y usos de los mismos. - Google Patents
Compuestos selectivos de peptido yy (pyy) y usos de los mismos.Info
- Publication number
- MX369818B MX369818B MX2016006053A MX2016006053A MX369818B MX 369818 B MX369818 B MX 369818B MX 2016006053 A MX2016006053 A MX 2016006053A MX 2016006053 A MX2016006053 A MX 2016006053A MX 369818 B MX369818 B MX 369818B
- Authority
- MX
- Mexico
- Prior art keywords
- pyy compounds
- compounds
- selective
- hpyy
- relates
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102100038991 Neuropeptide Y receptor type 2 Human genes 0.000 abstract 1
- 101710197945 Neuropeptide Y receptor type 2 Proteins 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13193082 | 2013-11-15 | ||
| US201361906020P | 2013-11-19 | 2013-11-19 | |
| EP14176725 | 2014-07-11 | ||
| PCT/EP2014/074476 WO2015071355A1 (en) | 2013-11-15 | 2014-11-13 | Selective pyy compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006053A MX2016006053A (es) | 2016-08-17 |
| MX369818B true MX369818B (es) | 2019-11-22 |
Family
ID=53056816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006053A MX369818B (es) | 2013-11-15 | 2014-11-13 | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9085637B2 (enExample) |
| EP (1) | EP3068421B1 (enExample) |
| JP (1) | JP6602760B2 (enExample) |
| KR (1) | KR20160075819A (enExample) |
| CN (1) | CN105722526B (enExample) |
| AU (1) | AU2014350197B2 (enExample) |
| BR (1) | BR112016010383A2 (enExample) |
| CA (1) | CA2929672A1 (enExample) |
| IL (1) | IL245045B (enExample) |
| MX (1) | MX369818B (enExample) |
| PL (1) | PL3068421T3 (enExample) |
| RS (1) | RS59026B1 (enExample) |
| SI (1) | SI3068421T1 (enExample) |
| TW (1) | TWI661835B (enExample) |
| WO (1) | WO2015071355A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012080471A1 (en) | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| MY171146A (en) | 2012-03-22 | 2019-09-27 | Novo Nordisk As | Compositions of glp-1 peptides and preparation thereof |
| CN105263957A (zh) * | 2013-05-02 | 2016-01-20 | 葛兰素史克知识产权开发有限公司 | 治疗肽 |
| PT2991671T (pt) | 2013-05-02 | 2018-11-05 | Novo Nordisk As | Dosagem oral de compostos de glp-1 |
| KR20160075819A (ko) | 2013-11-15 | 2016-06-29 | 노보 노르디스크 에이/에스 | 선택적 pyy 화합물 및 그것의 사용 |
| WO2015071356A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Hpyy(1 -36) having a beta-homoarginine substitution at position 35 |
| EP3307768B1 (en) * | 2015-06-12 | 2025-01-29 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| WO2017186896A1 (en) * | 2016-04-28 | 2017-11-02 | Novo Nordisk A/S | Semaglutide in cardiovascular conditions |
| WO2018083335A1 (en) | 2016-11-07 | 2018-05-11 | Novo Nordisk A/S | Dchbs-active esters of peg compounds and their use |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| MA49617A (fr) | 2017-07-19 | 2020-05-27 | Novo Nordisk As | Analogues d'egf(a), préparation, formulations et utilisations associées |
| HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
| US20210171598A1 (en) | 2017-12-01 | 2021-06-10 | University Of Copenhagen | Peptide hormone with one or more o-glycans |
| CA3087077A1 (en) * | 2018-01-09 | 2019-07-18 | Gila Therapeutics, Inc. | Compositions and methods for treating metabolic diseases |
| MA53076B1 (fr) | 2018-02-02 | 2023-11-30 | Novo Nordisk As | Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant |
| GB2573145A (en) * | 2018-04-26 | 2019-10-30 | Univ Ulster | Peptides for metabolic disease |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| TWI749381B (zh) * | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| EP4009957B1 (en) * | 2019-08-07 | 2023-10-11 | Novo Nordisk A/S | Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| CN114641303A (zh) | 2019-11-11 | 2022-06-17 | 勃林格殷格翰国际有限公司 | Npy2受体激动剂 |
| IL300239A (en) | 2020-08-07 | 2023-03-01 | Boehringer Ingelheim Int | Soluble NPY2 receptor agonists |
| EP4240749A1 (en) * | 2020-11-09 | 2023-09-13 | Embark Biotech ApS | Compounds and their use in treatment of tachykinin receptor mediated disorders |
| CN119677527A (zh) | 2022-08-18 | 2025-03-21 | 勃林格殷格翰国际有限公司 | 包含长效glp-1/胰高血糖素及npy2受体激动剂的组合疗法 |
| WO2025128624A2 (en) * | 2023-12-12 | 2025-06-19 | Carmot Therapeutics, Inc. | Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent |
| TW202540152A (zh) * | 2023-12-12 | 2025-10-16 | 美商卡默療法股份有限公司 | 具有經修飾之離胺酸殘基之雜合肽化合物 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ265452A (en) | 1993-03-29 | 1997-09-22 | Univ Cincinnati | Analogues of peptide yy, dimers and pharmaceutical compositions |
| US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
| WO1998020885A1 (en) | 1996-11-13 | 1998-05-22 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
| EP0908515A3 (en) | 1997-09-16 | 2000-04-26 | Smithkline Beecham Plc | Pancreatic polypeptide |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| JP2002517483A (ja) | 1998-06-08 | 2002-06-18 | シェーリング コーポレイション | 神経ペプチドｙ５レセプターアンタゴニスト |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| RU2275207C2 (ru) | 2000-12-14 | 2006-04-27 | Амилин Фармасьютикалз, Инк. | Способ снижения доступности питательного вещества, способ подавления аппетита |
| US6589938B2 (en) | 2001-06-29 | 2003-07-08 | National University Of Singapore | Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| IL160983A0 (en) | 2001-09-24 | 2004-08-31 | Imp College Innovations Ltd | Use of pyy for preparation of a medicament for modification of feeding behavior |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| EP1583549A4 (en) | 2003-01-17 | 2006-10-04 | Sod Conseils Rech Applic | YY PEPTIDE ANALOGS |
| US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
| JP2007537981A (ja) | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の血漿タンパク質親和性タグ |
| EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| IN2012DN03921A (enExample) | 2004-02-11 | 2015-09-04 | Amylin Pharmaceuticals Inc | |
| WO2005077094A2 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| MXPA06010347A (es) | 2004-03-17 | 2007-06-19 | 7Tm Pharma As | Agonistas de receptor selectivo de y2 para intervenciones terapeuticas. |
| EP1786458A2 (en) | 2004-03-17 | 2007-05-23 | 7TM Pharma A/S | Y2/y4 selective receptor agonists for therapeutic interventions |
| CN1933848A (zh) | 2004-03-17 | 2007-03-21 | 7Tm制药联合股份有限公司 | 用于治疗性干预的y2选择性受体激动剂 |
| CA2560174A1 (en) | 2004-03-17 | 2005-09-29 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| BRPI0512988A (pt) | 2004-07-08 | 2008-04-22 | Novo Nordisk As | método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica |
| US7994119B2 (en) | 2004-07-19 | 2011-08-09 | University Of Cincinnati | Compounds for control of appetite |
| WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
| US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| JP2009500453A (ja) | 2005-07-11 | 2009-01-08 | ナステック ファーマスーティカル カンパニー インク． | 向上されたｐｙｙの粘膜送達用製剤 |
| KR20080031414A (ko) | 2005-07-18 | 2008-04-08 | 노보 노르디스크 에이/에스 | 비만치료에 사용하기 위한 신규 펩티드 |
| JP2009508886A (ja) | 2005-09-21 | 2009-03-05 | ７ティーエム ファーマ エイ／エス | 治療的介入のためのｙ２選択性レセプターアゴニスト |
| AU2005337116A1 (en) | 2005-09-21 | 2007-04-12 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
| AU2006324076A1 (en) | 2005-12-07 | 2007-06-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor-agonists |
| WO2007068718A1 (en) | 2005-12-14 | 2007-06-21 | Novo Nordisk A/S | Polypeptide protracting tags |
| US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
| JP5412273B2 (ja) | 2006-03-21 | 2014-02-12 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | ペプチド−ぺプチダーゼ阻害剤及びその使用 |
| GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| US20090099074A1 (en) | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
| US20100016237A1 (en) | 2007-01-18 | 2010-01-21 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| WO2008087190A2 (en) | 2007-01-18 | 2008-07-24 | Novo Nordisk A/S | Use of peptides in combination with surgical intervention for the treatment of obesity |
| GB0708226D0 (en) | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
| EP2167535A2 (en) | 2007-07-09 | 2010-03-31 | Imperial Innovations Limited | Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour |
| JP5606314B2 (ja) | 2007-09-05 | 2014-10-15 | ノボ・ノルデイスク・エー／エス | Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途 |
| AU2008303910A1 (en) | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of stresscopin-related peptide as a therapeutic agent |
| US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| KR20110017874A (ko) | 2008-05-16 | 2011-02-22 | 노보 노르디스크 에이/에스 | 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제 |
| US8299023B2 (en) | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
| GB0817067D0 (en) | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
| MX2011004427A (es) | 2008-11-05 | 2011-05-31 | Hoffmann La Roche | Agonistas del receptor de neuropeptido-2 (y-2r) y usos de los mismos. |
| UA102432C2 (ru) | 2009-02-20 | 2013-07-10 | Іпсен Фарма С.А.С. | Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y |
| WO2011033068A1 (en) | 2009-09-18 | 2011-03-24 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| WO2011045232A2 (en) | 2009-10-13 | 2011-04-21 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor (y-2r) agonists |
| JP2013510829A (ja) | 2009-11-13 | 2013-03-28 | ノヴォ ノルディスク アー／エス | 長時間作用型ｙ２受容体アゴニスト |
| EP2560675A1 (en) | 2010-04-20 | 2013-02-27 | Novo Nordisk A/S | Long-acting gastrin derivatives |
| ES2935300T3 (es) * | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | Combiterapia |
| GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| US20150141336A1 (en) | 2012-05-29 | 2015-05-21 | Novo Nordisk A/S | Pancreatic Peptide Compounds and Use |
| CN105263957A (zh) | 2013-05-02 | 2016-01-20 | 葛兰素史克知识产权开发有限公司 | 治疗肽 |
| KR20160075819A (ko) | 2013-11-15 | 2016-06-29 | 노보 노르디스크 에이/에스 | 선택적 pyy 화합물 및 그것의 사용 |
| WO2015071356A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Hpyy(1 -36) having a beta-homoarginine substitution at position 35 |
| EP3307768B1 (en) * | 2015-06-12 | 2025-01-29 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
-
2014
- 2014-11-13 KR KR1020167015805A patent/KR20160075819A/ko not_active Withdrawn
- 2014-11-13 JP JP2016531028A patent/JP6602760B2/ja active Active
- 2014-11-13 AU AU2014350197A patent/AU2014350197B2/en not_active Ceased
- 2014-11-13 PL PL14798834T patent/PL3068421T3/pl unknown
- 2014-11-13 CN CN201480062213.5A patent/CN105722526B/zh active Active
- 2014-11-13 TW TW103139321A patent/TWI661835B/zh not_active IP Right Cessation
- 2014-11-13 WO PCT/EP2014/074476 patent/WO2015071355A1/en not_active Ceased
- 2014-11-13 US US14/540,474 patent/US9085637B2/en active Active
- 2014-11-13 CA CA2929672A patent/CA2929672A1/en not_active Withdrawn
- 2014-11-13 RS RS20190792A patent/RS59026B1/sr unknown
- 2014-11-13 MX MX2016006053A patent/MX369818B/es active IP Right Grant
- 2014-11-13 BR BR112016010383A patent/BR112016010383A2/pt not_active Application Discontinuation
- 2014-11-13 EP EP14798834.9A patent/EP3068421B1/en active Active
- 2014-11-13 SI SI201431251T patent/SI3068421T1/sl unknown
- 2014-11-13 US US15/036,201 patent/US10246497B2/en active Active
-
2016
- 2016-04-11 IL IL245045A patent/IL245045B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2929672A1 (en) | 2015-05-21 |
| CN105722526A (zh) | 2016-06-29 |
| US10246497B2 (en) | 2019-04-02 |
| AU2014350197A1 (en) | 2016-05-05 |
| US20160289283A1 (en) | 2016-10-06 |
| SI3068421T1 (sl) | 2019-08-30 |
| TWI661835B (zh) | 2019-06-11 |
| JP6602760B2 (ja) | 2019-11-06 |
| AU2014350197B2 (en) | 2018-10-04 |
| US9085637B2 (en) | 2015-07-21 |
| WO2015071355A1 (en) | 2015-05-21 |
| IL245045A0 (en) | 2016-05-31 |
| IL245045B (en) | 2019-09-26 |
| KR20160075819A (ko) | 2016-06-29 |
| CN105722526B (zh) | 2020-12-08 |
| TW201605467A (zh) | 2016-02-16 |
| JP2017505284A (ja) | 2017-02-16 |
| PL3068421T3 (pl) | 2019-11-29 |
| EP3068421B1 (en) | 2019-04-17 |
| BR112016010383A2 (pt) | 2017-12-05 |
| RS59026B1 (sr) | 2019-08-30 |
| MX2016006053A (es) | 2016-08-17 |
| EP3068421A1 (en) | 2016-09-21 |
| US20150152150A1 (en) | 2015-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MY183536A (en) | Pharmaceutical compositions comprising azd9291 | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MY181181A (en) | Fgf21 derivatives and uses thereof | |
| BR112015030387A2 (pt) | compostos de pirazol como moduladores de fshr e usos dos mesmos | |
| PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
| PH12015502755A1 (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| PH12017501736B1 (en) | Indole derivatives | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
| MX2015006997A (es) | Composicion farmaceutica. | |
| GR1008804B (el) | Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα | |
| IN2013MU03656A (enExample) | ||
| UA114792C2 (uk) | Коагоніст глюкагонового рецептора/glp-1-рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |